patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_313680 | REC_0006901 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 8.4 | 73 | male | 2 | 12 | 4.2 | 2 | entrectinib 600 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:58.546316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252581 | REC_0006902 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.6 | 39 | male | 0 | 9 | 6.2 | 8 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.546551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342520 | REC_0006903 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.2 | 59 | female | 1 | 31 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:35:58.546784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274008 | REC_0006904 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.8 | 64 | female | 1 | 0 | 5.3 | 7 | pembrolizumab 200 mg q3w | 16.4 | false | MSS | 2026-03-15T05:35:58.547079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265364 | REC_0006905 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 9.8 | 57 | female | 0 | 14 | 5.9 | 2 | osimertinib 80 mg daily | 22.3 | true | MSS | 2026-03-15T05:35:58.547318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355252 | REC_0006906 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 15.8 | 71 | female | 2 | 19 | 7 | 4 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.547549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263445 | REC_0006907 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.8 | 66 | female | 0 | 20 | 6.2 | 7 | osimertinib 80 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:58.547781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633836 | REC_0006908 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 16.2 | 60 | female | 1 | 15 | 5.9 | 7 | alectinib 600 mg BID | 8 | false | MSI-H | 2026-03-15T05:35:58.548016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153939 | REC_0006909 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 9 | 85 | female | 1 | 18 | 5.7 | 2 | osimertinib 80 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:58.548280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109777 | REC_0006910 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 13.8 | 73 | male | 2 | 25 | 5.5 | 0 | osimertinib 80 mg daily | 34.8 | true | MSS | 2026-03-15T05:35:58.548516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333162 | REC_0006911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 17.2 | 65 | female | 0 | 24 | 6.4 | 6 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:58.548753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605531 | REC_0006912 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 18.5 | 64 | male | 1 | 18 | 3.9 | 2 | sotorasib 960 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.548993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388738 | REC_0006913 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 10.7 | 65 | female | 1 | 10 | 6.2 | 5 | alectinib 600 mg BID | 12.5 | true | MSI-H | 2026-03-15T05:35:58.549232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700101 | REC_0006914 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.1 | 58 | female | 1 | 66 | 3.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:35:58.549463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485214 | REC_0006915 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.7 | 84 | female | 2 | 18 | 3.9 | 6 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:58.549693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528700 | REC_0006916 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.8 | 82 | female | 2 | 26 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:58.549922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444351 | REC_0006917 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.5 | 74 | female | 2 | 25 | 5.3 | 5 | alectinib 600 mg BID | 6.7 | true | MSS | 2026-03-15T05:35:58.550201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251061 | REC_0006918 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.6 | 64 | male | 1 | 23 | 4.5 | 1 | sotorasib 960 mg daily | 8.1 | false | MSS | 2026-03-15T05:35:58.550436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161632 | REC_0006919 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 13.9 | 52 | female | 0 | 14 | 5.7 | 5 | sotorasib 960 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:58.550671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577989 | REC_0006920 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.2 | 75 | male | 1 | 18 | 6.9 | 7 | alectinib 600 mg BID | 8.9 | true | MSI-H | 2026-03-15T05:35:58.550909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252672 | REC_0006921 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 9.1 | 65 | female | 1 | 11 | 5.9 | 5 | alectinib 600 mg BID | 11.8 | true | MSS | 2026-03-15T05:35:58.551141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183014 | REC_0006922 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.9 | 64 | female | 0 | 14 | 4.8 | 5 | osimertinib 80 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:58.551372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421196 | REC_0006923 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 15 | 72 | female | 3 | 11 | 5.5 | 6 | entrectinib 600 mg daily | 6.5 | false | MSI-H | 2026-03-15T05:35:58.551603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778972 | REC_0006924 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.1 | 61 | male | 1 | 16 | 6.2 | 7 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.551837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753906 | REC_0006925 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.4 | 66 | female | 1 | 5 | 4.6 | 2 | pembrolizumab 200 mg q3w | 23.5 | false | MSS | 2026-03-15T05:35:58.552067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733938 | REC_0006926 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 25 | 9.2 | 70 | female | 2 | 11 | 6.4 | 0 | pembrolizumab 200 mg q3w | 27.4 | false | MSS | 2026-03-15T05:35:58.552402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406217 | REC_0006927 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.3 | 63 | male | 0 | 28 | 3.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.6 | true | MSS | 2026-03-15T05:35:58.552639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626916 | REC_0006928 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 7.5 | 71 | male | 0 | 15 | 5.7 | 6 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:58.552875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258171 | REC_0006929 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 15.6 | 69 | male | 1 | 14 | 6.4 | 1 | entrectinib 600 mg daily | 23.3 | false | MSS | 2026-03-15T05:35:58.553113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395593 | REC_0006930 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 19.7 | 65 | female | 0 | 13 | 5.4 | 8 | osimertinib 80 mg daily | 6.5 | true | MSS | 2026-03-15T05:35:58.553409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501811 | REC_0006931 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 15.5 | 68 | female | 0 | 21 | 6.6 | 5 | entrectinib 600 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:58.553650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670369 | REC_0006932 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 5.8 | 64 | female | 0 | 20 | 4.8 | 3 | entrectinib 600 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:58.553884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501618 | REC_0006933 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 11.4 | 72 | male | 0 | 17 | 4.4 | 1 | sotorasib 960 mg daily | 15 | false | MSI-H | 2026-03-15T05:35:58.554121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516114 | REC_0006934 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.2 | 72 | female | 1 | 17 | 6 | 2 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.554351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128186 | REC_0006935 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.2 | 66 | female | 1 | 0 | 4.8 | 6 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:58.554580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400602 | REC_0006936 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 14 | 79 | female | 2 | 11 | 5.8 | 2 | osimertinib 80 mg daily | 29.9 | true | MSS | 2026-03-15T05:35:58.554812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312689 | REC_0006937 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 11.4 | 77 | female | 2 | 7 | 5.5 | 1 | osimertinib 80 mg daily | 22.6 | true | MSS | 2026-03-15T05:35:58.555042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500830 | REC_0006938 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 19.9 | 71 | male | 2 | 16 | 5.3 | 1 | osimertinib 80 mg daily | 23.6 | true | MSS | 2026-03-15T05:35:58.555278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568070 | REC_0006939 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 12.4 | 63 | female | 1 | 18 | 3.8 | 9 | entrectinib 600 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.555512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838473 | REC_0006940 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.4 | 68 | male | 0 | 13 | 5.7 | 7 | sotorasib 960 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:58.555744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171208 | REC_0006941 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.9 | 78 | male | 2 | 10 | 6.6 | 7 | alectinib 600 mg BID | 16.7 | false | MSI-H | 2026-03-15T05:35:58.555978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132007 | REC_0006942 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 11.3 | 61 | male | 1 | 16 | 4.5 | 7 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:35:58.556311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772972 | REC_0006943 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15 | 70 | female | 1 | 16 | 5.2 | 7 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.556625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687888 | REC_0006944 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.9 | 68 | female | 1 | 21 | 7.7 | 7 | sotorasib 960 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:58.556869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970776 | REC_0006945 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.6 | 59 | male | 1 | 18 | 4.3 | 7 | sotorasib 960 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:58.557108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933556 | REC_0006946 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.5 | 70 | female | 2 | 34 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 7 | true | MSS | 2026-03-15T05:35:58.557338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380377 | REC_0006947 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 13.5 | 72 | female | 0 | 16 | 4.5 | 1 | entrectinib 600 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:58.557570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429666 | REC_0006948 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.7 | 55 | female | 0 | 12 | 6.3 | 6 | entrectinib 600 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:58.557805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364425 | REC_0006949 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 7.1 | 85 | female | 1 | 69 | 3.5 | 4 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:58.558033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170556 | REC_0006950 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.7 | 64 | female | 0 | 23 | 4.8 | 5 | alectinib 600 mg BID | 4.5 | true | MSS | 2026-03-15T05:35:58.558267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456768 | REC_0006951 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 5.4 | 70 | female | 1 | 47 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.8 | true | MSS | 2026-03-15T05:35:58.558495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671656 | REC_0006952 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 12.2 | 67 | female | 1 | 14 | 5 | 0 | entrectinib 600 mg daily | 33.7 | false | MSI-H | 2026-03-15T05:35:58.558733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216482 | REC_0006953 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.3 | 64 | female | 1 | 14 | 5.6 | 6 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.558966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649242 | REC_0006954 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 16.6 | 55 | male | 0 | 12 | 7.9 | 6 | osimertinib 80 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:35:58.559202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825288 | REC_0006955 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.4 | 78 | male | 2 | 0 | 6.5 | 2 | entrectinib 600 mg daily | 11 | true | MSS | 2026-03-15T05:35:58.559438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275914 | REC_0006956 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.5 | 67 | female | 1 | 12 | 4.4 | 7 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:35:58.559715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684447 | REC_0006957 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 14.3 | 55 | female | 0 | 26 | 8.5 | 1 | osimertinib 80 mg daily | 24.3 | false | MSS | 2026-03-15T05:35:58.559955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289396 | REC_0006958 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 9.3 | 80 | male | 2 | 19 | 5.2 | 0 | sotorasib 960 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:58.560288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402772 | REC_0006959 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.8 | 78 | male | 0 | 12 | 3 | 2 | entrectinib 600 mg daily | 21.1 | true | MSS | 2026-03-15T05:35:58.560537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464030 | REC_0006960 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 8.3 | 66 | female | 0 | 15 | 6.5 | 1 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:35:58.560767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184671 | REC_0006961 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 8 | 74 | female | 2 | 22 | 8.1 | 0 | sotorasib 960 mg daily | 37.4 | true | MSS | 2026-03-15T05:35:58.560996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942229 | REC_0006962 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 27 | 10.7 | 63 | male | 1 | 16 | 4.7 | 0 | pembrolizumab 200 mg q3w | 24.4 | true | MSS | 2026-03-15T05:35:58.561229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788277 | REC_0006963 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13 | 71 | female | 1 | 10 | 6.6 | 7 | entrectinib 600 mg daily | 18.8 | true | MSI-H | 2026-03-15T05:35:58.561461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829124 | REC_0006964 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.5 | 55 | male | 0 | 2 | 6.6 | 1 | alectinib 600 mg BID | 18.2 | false | MSS | 2026-03-15T05:35:58.561698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858927 | REC_0006965 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 4.3 | 75 | female | 3 | 10 | 4.8 | 5 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:58.561928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897649 | REC_0006966 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.7 | 75 | female | 2 | 18 | 5.6 | 7 | osimertinib 80 mg daily | 17.3 | false | MSI-H | 2026-03-15T05:35:58.562159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706991 | REC_0006967 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.8 | 57 | female | 1 | 9 | 4.8 | 7 | alectinib 600 mg BID | 13.1 | true | MSI-H | 2026-03-15T05:35:58.562396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940500 | REC_0006968 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 13.6 | 62 | female | 1 | 17 | 5.4 | 2 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:58.562631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321303 | REC_0006969 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 10.9 | 81 | male | 3 | 17 | 6.2 | 6 | osimertinib 80 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:58.562933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694212 | REC_0006970 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 2.2 | 79 | male | 2 | 17 | 6.8 | 7 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:58.563170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908348 | REC_0006971 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.9 | 70 | female | 1 | 15 | 4.5 | 5 | alectinib 600 mg BID | 11.1 | false | MSI-H | 2026-03-15T05:35:58.563404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904887 | REC_0006972 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 9.6 | 74 | female | 2 | 19 | 5.1 | 1 | osimertinib 80 mg daily | 20.3 | true | MSS | 2026-03-15T05:35:58.563635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262082 | REC_0006973 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 13 | 55 | male | 1 | 14 | 5.1 | 0 | osimertinib 80 mg daily | 42 | false | MSI-H | 2026-03-15T05:35:58.563870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427812 | REC_0006974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 19.5 | 58 | female | 0 | 10 | 5.7 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.564136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165702 | REC_0006975 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.4 | 58 | female | 1 | 19 | 7.1 | 4 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.564378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942456 | REC_0006976 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.4 | 67 | female | 0 | 13 | 4.4 | 6 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:58.564612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310274 | REC_0006977 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.2 | 59 | female | 1 | 9 | 6.1 | 6 | entrectinib 600 mg daily | 4.2 | true | MSS | 2026-03-15T05:35:58.564847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640870 | REC_0006978 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.5 | 57 | male | 0 | 16 | 2.6 | 1 | alectinib 600 mg BID | 29.1 | false | MSS | 2026-03-15T05:35:58.565084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157551 | REC_0006979 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.1 | 70 | female | 1 | 17 | 5.5 | 2 | entrectinib 600 mg daily | 19.6 | true | MSS | 2026-03-15T05:35:58.565318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946575 | REC_0006980 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.1 | 64 | male | 0 | 16 | 7.4 | 8 | osimertinib 80 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:58.565552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384200 | REC_0006981 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.7 | 64 | female | 1 | 15 | 5.1 | 5 | entrectinib 600 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:58.565783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409792 | REC_0006982 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.3 | 71 | female | 2 | 16 | 4.6 | 5 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:58.566068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405382 | REC_0006983 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 7.9 | 78 | male | 2 | 23 | 8.2 | 4 | osimertinib 80 mg daily | 18.8 | true | MSS | 2026-03-15T05:35:58.566307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758971 | REC_0006984 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.5 | 79 | female | 1 | 13 | 3.9 | 7 | alectinib 600 mg BID | 18.5 | false | MSS | 2026-03-15T05:35:58.566537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246458 | REC_0006985 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 11.1 | 61 | male | 0 | 15 | 7.4 | 2 | osimertinib 80 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:58.566774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814404 | REC_0006986 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13 | 69 | female | 1 | 13 | 5.6 | 3 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:58.567011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779965 | REC_0006987 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 15.2 | 77 | male | 1 | 12 | 6 | 7 | entrectinib 600 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:58.567248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771945 | REC_0006988 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.4 | 65 | female | 0 | 7 | 6.4 | 7 | sotorasib 960 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:58.567479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113440 | REC_0006989 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 11.3 | 78 | female | 2 | 12 | 7.9 | 2 | osimertinib 80 mg daily | 24 | true | MSS | 2026-03-15T05:35:58.567712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731322 | REC_0006990 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13 | 65 | male | 0 | 23 | 4.9 | 2 | alectinib 600 mg BID | 4.2 | false | MSS | 2026-03-15T05:35:58.567950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460387 | REC_0006991 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.9 | 65 | female | 1 | 31 | 6.8 | 2 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:58.568262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173040 | REC_0006992 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 2.8 | 75 | female | 0 | 14 | 3.5 | 5 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:35:58.568526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822793 | REC_0006993 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.3 | 61 | male | 1 | 11 | 6.1 | 6 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:58.568766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257112 | REC_0006994 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.2 | 65 | male | 1 | 15 | 4.2 | 6 | entrectinib 600 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:35:58.569005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297524 | REC_0006995 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 18.2 | 66 | female | 0 | 17 | 6.1 | 7 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.569325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266908 | REC_0006996 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.6 | 77 | female | 1 | 11 | 4 | 7 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:58.569567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488384 | REC_0006997 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.9 | 65 | female | 0 | 16 | 5.6 | 5 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.569803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589130 | REC_0006998 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 14.4 | 58 | male | 0 | 13 | 4 | 2 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:58.570041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476003 | REC_0006999 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 12 | 54 | male | 0 | 2 | 3 | 6 | osimertinib 80 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:58.570281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211756 | REC_0007000 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 15.2 | 70 | female | 1 | 15 | 6.6 | 4 | sotorasib 960 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:35:58.570516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.